Mar 02, 2026
Summary The U.S. FDA approved Vanda Pharmaceuticals’ BYSANTI (milsaperidone) for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder. BYSANTI is built on the pharmacologic framework of FANAPT (iloperidone). Vanda’s stock surged nearly 40% after BYSANTI’s approval,...
Read More...
Understanding Bone Densitometers: Technology, Applications, and Impact on Bone Health
Nov 04, 2025
Wireless Brain Sensors: Revolutionizing Neuroscience and Healthcare
Oct 28, 2025
Discover How Learning Disability Treatment Landscape is Evolving with the Emergence of Digital Assistant Technologies
Jul 04, 2025
A New Era for Multiple Myeloma Treatment: Bispecific Antibodies Enter the Fray
Jun 10, 2025
-Agonist.png "Toll-like Receptors Agonist")
Newsletter/Whitepaper